Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518301 | 0.89 | HSD11B1 (0.51) | HSD11B1P2RX7HRH3TP53ALDH1A1 | |
| SCHEMBL4504216 | 0.87 | HSD11B1 (0.47) | HSD11B1HRH3 | |
| SCHEMBL4519281 | 0.86 | HSD11B1 (0.53) | HSD11B1P2RX7HRH3LMNA | |
| SCHEMBL4512444 | 0.86 | HSD11B1 (0.54) | HSD11B1P2RX7ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3000826 | 0.85 | HSD11B1 (0.56) | HSD11B1P2RX7 | |
| SCHEMBL2991795 | 0.85 | HSD11B1 (0.56) | HSD11B1P2RX7 | |
| SCHEMBL2995925 | 0.85 | HSD11B1 (0.65) | HSD11B1HRH3TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL4522654 | 0.85 | HSD11B1 (0.49) | HSD11B1P2RX7HRH3TP53ALDH1A1 | |
| SCHEMBL3555104 | 0.84 | HSD11B1 (0.55) | HSD11B1P2RX7ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2990822 | 0.83 | HSD11B1 (0.54) | HSD11B1P2RX7ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885P2RX7 3946/4885HRH3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.